179 related articles for article (PubMed ID: 23638236)
1. Primary hepatosplenic CD5-positive diffuse large B-cell lymphoma: a case report with literature review.
Zhang X; Sun M; Zhang L; Shao H
Int J Clin Exp Pathol; 2013; 6(5):985-9. PubMed ID: 23638236
[TBL] [Abstract][Full Text] [Related]
2. Primary hepatic and hepatosplenic diffuse large B-cell lymphomas with intrasinusoidal and interstitial lymphomatous infiltration.
Kashimura M; Murayama K; Kojima M
Int J Surg Pathol; 2013 Oct; 21(5):531-4. PubMed ID: 23610457
[TBL] [Abstract][Full Text] [Related]
3. Primary splenic diffuse large B-cell lymphoma manifesting in red pulp.
Kashimura M; Noro M; Akikusa B; Okuhara A; Momose S; Miura I; Kojima M; Tamaru J
Virchows Arch; 2008 Nov; 453(5):501-9. PubMed ID: 18818942
[TBL] [Abstract][Full Text] [Related]
4. De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma.
Kroft SH; Howard MS; Picker LJ; Ansari MQ; Aquino DB; McKenna RW
Am J Clin Pathol; 2000 Oct; 114(4):523-33. PubMed ID: 11026098
[TBL] [Abstract][Full Text] [Related]
5. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
Yamaguchi M; Seto M; Okamoto M; Ichinohasama R; Nakamura N; Yoshino T; Suzumiya J; Murase T; Miura I; Akasaka T; Tamaru J; Suzuki R; Kagami Y; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Blood; 2002 Feb; 99(3):815-21. PubMed ID: 11806981
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma.
Shimono J; Miyoshi H; Kiyasu J; Sato K; Kamimura T; Eto T; Miyagishima T; Nagafuji K; Teshima T; Ohshima K
Br J Haematol; 2017 Sep; 178(5):719-727. PubMed ID: 28493517
[TBL] [Abstract][Full Text] [Related]
7. A Case Presenting with Splenic Infarct Diagnosed as Primary Bone Marrow CD5 Positive DLBCL: A Clinicopathological Correlation.
Bansal A; Mittal S; Dass J; Gupta N; Agarwal PK; Kotwal J
Indian J Hematol Blood Transfus; 2016 Jun; 32(Suppl 1):159-62. PubMed ID: 27408381
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
[TBL] [Abstract][Full Text] [Related]
9. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
[TBL] [Abstract][Full Text] [Related]
11. De Novo CD5-Positive Diffuse Large B-Cell Lymphoma: Report of a Case Presenting With Cutaneous Involvement and Featuring Extensive Intravascular Dissemination on Postmortem Examination.
Úbeda Romero A; Santonja C; Blanco García A; Requena L; Rodríguez Pinilla SM
Int J Surg Pathol; 2016 Dec; 24(8):763-768. PubMed ID: 27431754
[TBL] [Abstract][Full Text] [Related]
12. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases.
Li Y; Hu S; Zuo Z; Hong M; Lin P; Li S; Konoplev S; Wang Z; Khoury JD; Young KH; Medeiros LJ; Yin CC
Mod Pathol; 2015 Jun; 28(6):787-98. PubMed ID: 25743023
[TBL] [Abstract][Full Text] [Related]
13. De Novo CD5+ Primary Gastrointestinal Diffuse Large B-Cell Lymphoma: Challenges With Treatment and Clinical Course.
Ramachandran P; Sahni S; Wang JC
J Investig Med High Impact Case Rep; 2019; 7():2324709619893546. PubMed ID: 31814435
[TBL] [Abstract][Full Text] [Related]
14. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities.
Kano R; Masaie H; Hino A; Yasuoka H; Nagata S; Ishikawa J; Nakatsuka SI
Diagn Pathol; 2018 Jul; 13(1):46. PubMed ID: 30041681
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment with combination of plasma exchange and chemotherapy for CD5-positive primary hepatosplenic diffuse large B-cell lymphoma complicated with acute liver injury].
Sato M; Kuroda H; Yoshida M; Usami M; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Kanari Y; Matsuno T; Jomen W; Kato J
Rinsho Ketsueki; 2014 Aug; 55(8):958-64. PubMed ID: 25186486
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases.
Tagawa H; Tsuzuki S; Suzuki R; Karnan S; Ota A; Kameoka Y; Suguro M; Matsuo K; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
Cancer Res; 2004 Sep; 64(17):5948-55. PubMed ID: 15342373
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
Na HY; Choe JY; Shin SA; Kim HJ; Han JH; Kim HK; Oh SH; Kim JE
PLoS One; 2019; 14(10):e0224247. PubMed ID: 31644584
[TBL] [Abstract][Full Text] [Related]
19. [Tumors of lymphoid and hematopoietic tissue of spleen: a clinicopathologic analysis of 53 cases].
Chen DB; Shen DH; Zhang H; Wang Y; Song QJ; Yang SM; Fang XZ
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):775-781. PubMed ID: 29136691
[No Abstract] [Full Text] [Related]
20. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
